List of bibliographic references
Number of relevant bibliographic references: 50.
[0-20] [
0 - 20][
0 - 50][
20-40]
| Ident. | Authors (with country if any) | Title |
|---|
| 000055 (2021) |
Nurullah Okumu ; Ne E Demirtürk ; R Za Aytaç Çetinkaya ; Rahmet Güner ; Smail Ya Ar Avc ; Semiha Orhan ; Petek Konya ; Bengü Aylan ; Ay Egül Karalezli ; Levent Yamanel ; Bircan Kayaaslan ; Gülden Y Lmaz ; Ümit Sava Ç ; Fatma Eser ; Gürhan Ta K N | Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. |
| 000081 (2021) |
Rujipas Sirijatuphat ; Yupin Suputtamongkol ; Nasikarn Angkasekwinai ; Navin Horthongkham ; Methee Chayakulkeeree ; Pinyo Rattanaumpawan ; Pornpan Koomanachai ; Susan Assanasen ; Yong Rongrungruang ; Nitipatana Chierakul ; Ranistha Ratanarat ; Anupop Jitmuang ; Walaiporn Wangchinda ; Wannee Kantakamalakul | Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital. |
| 000160 (2021) |
Hany M. Dabbous ; Manal H. El-Sayed ; Gihan El Assal ; Hesham Elghazaly ; Fatma F S. Ebeid ; Ahmed F. Sherief ; Maha Elgaafary ; Ehab Fawzy ; Sahar M. Hassany ; Ahmed R. Riad ; Mohamed A. Tageldin | Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. |
| 000258 (2021) |
Fabio Cruciani ; Laura Amato ; Franco De Crescenzo ; Zuzana Mitrova ; Rosella Saulle ; Simona Vecchi ; Marina Davoli | [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.] |
| 000294 (2021) |
Rahmet Guner ; Imran Hasanoglu ; Bircan Kayaaslan ; Adalet Aypak ; Esragul Akinci ; Hurrem Bodur ; Fatma Eser ; Ayse Kaya Kalem ; Orhan Kucuksahin ; Ihsan Ates ; Aliye Bastug ; Yasemin Tezer Tekce ; Zeynep Bilgic ; Fahriye Melis Gursoy ; Hatice Nisa Akca ; Seval Izdes ; Deniz Erdem ; Emra Asfuroglu ; Habibe Hezer ; Hatice Kilic ; Musa C Vak ; Sibel Aydogan ; Turan Buzgan | Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir. |
| 000382 (2021) |
Katharina Habler ; Mathias Brügel ; Daniel Teupser ; Uwe Liebchen ; Christina Scharf ; Ulf Schönermarck ; Michael Vogeser ; Michael Paal | Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum. |
| 000436 (2021) |
Farah Daou ; Gretta Abou-Sleymane ; Danielle A. Badro ; Nagham Khanafer ; Mansour Tobaiqy ; Achraf Al Faraj | The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. |
| 000468 (2021) |
Dorna Kheirabadi ; Fatemeh Haddad ; Razieh S. Mousavi-Roknabadi ; Mohammad Rezaeisadrabadi ; Hamidreza Dehghan ; Aylar Fazlzadeh | A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. |
| 000480 (2021) |
Florence Rodgers ; Toby Pepperrell ; Sarai Keestra ; Victoria Pilkington | Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs. |
| 000493 (2021) |
Ambedkar Kumar Yadav ; Siwan Wen ; Xianghuai Xu ; Li Yu | Antiviral treatment in COVID-19: which is the most promising?-a narrative review. |
| 000518 (2020) |
Lenka Petroušová ; Simona Da Silva ; Lud K Rožnovsk ; Irena Martinková | [Clinical progression of the first wave of novel coronavirus infection in Ostrava]. |
| 000642 (2020) |
N. Trivedi ; A. Verma ; D. Kumar | Possible treatment and strategies for COVID-19: review and assessment. |
| 000686 (2020) |
Hilary Miller-Handley ; Keith Luckett ; Amit Govil | Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. |
| 000691 (2020) |
Immacolata Ambrosino ; Elena Barbagelata ; Graziamaria Corbi ; Tiziana Ciarambino ; Cecilia Politi ; Anna Maria Moretti | Gender differences in treatment of Coronavirus Disease-2019. |
| 000751 (2021) |
Sanjay Kumar Mishra ; Timir Tripathi | One year update on the COVID-19 pandemic: Where are we now? |
| 000846 (2020) |
Murat Çap ; Önder Bilge ; Ferhat I K ; Cengiz Burak ; Ali Karagöz ; Ümit Nci ; Abdurrahman Akyüz ; Burhan Aslan ; Bernas Alt Nta ; Rojhat Alt Nda ; Lyas Kaya ; Mehmet Ahin Ad Yaman ; Muhammed Süleymano Lu ; Afak Kaya ; Erkan Baysal | The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019. |
| 000847 (2021) |
Faryal Khamis ; Hanan Al Naabi ; Adil Al Lawati ; Zaiyana Ambusaidi ; Mariam Al Sharji ; Umkulthum Al Barwani ; Nenad Pandak ; Zakariya Al Balushi ; Maher Al Bahrani ; Issa Al Salmi ; Ibrahim Al-Zakwani | Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. |
| 000851 (2020) |
Woon Yi Law ; Mohd Razip Asaruddin ; Showkat Ahamd Bhawani ; Samsur Mohamad | Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as MPro inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). |
| 000858 (2020) |
Gayathri Vaidyanathan | Scientists criticize use of unproven COVID drugs in India. |
| 000917 (2020) |
Mohammad Bosaeed ; Ebrahim Mahmoud ; Mohammad Hussein ; Ahmad Alharbi ; Abdulrahman Alsaedy ; Adel Alothman ; Majed Aljeraisy ; Hajar Alqahtani ; Marwan Nashabat ; Badriah Almutairi ; Manar Almaghaslah ; Omar Aldibasi ; Sameera Aljohani ; Abderrezak Bouchama ; Yaseen Arabi ; Ahmad Alaskar | A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial. |
| 000919 (2021) |
Havva Kocayi It ; Kezban Özmen Süner ; Yakup Tomak ; Gürkan Demir ; Selçuk Yaylac ; Hamad Dheir ; Ertu Rul Güçlü ; Ali Fuat Erdem | Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/MedMesh.i -k "Amides"
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/MedMesh.i \
-Sk "Amides" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= indexItem
|index= MedMesh.i
|clé= Amides
}}
| This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021 |  |
